Group B Streptococcal Infection Clinical Trial
Official title:
A Multicentre, Multinational, Parallel Group, Observer-blind, Randomised, Placebo-controlled Study on the Group B Streptococcus Vaccine (GBS-NN/NN2), Investigating the Immunogenicity and Safety of Four Vaccination Regimens in Pregnant Woman, Assessing IgG Specific to AlpN Proteins in Cord Blood and Maternal Blood, and the Safety Profile in Mother and Infant up to 6 Months Post-delivery
Verified date | March 2024 |
Source | Minervax ApS |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase II, multicentre, multinational, randomized, parallel group, placebo-controlled study of four vaccination regimens in healthy pregnant women. There will be 5 treatment groups; three groups of 60 participants will receive will receive two doses of GBS-NN/NN2 vaccine and one dose of placebo (saline); one group of 60 participants will receive one dose of GBS-NN/NN2 vaccine and two doses of placebo (saline), and one group of 60 participants will receive three doses of placebo (saline).
Status | Completed |
Enrollment | 272 |
Est. completion date | October 18, 2023 |
Est. primary completion date | April 26, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | N/A and older |
Eligibility | Inclusion Criteria: 1. Healthy pregnant woman above the legally defined age of consent at the time of screening 2. Carrying a normal singleton pregnancy, and is at 21+0 to 23+6 weeks GA at the planned tme of the 1st vaccination, as established by first/second trimester ultrasound examination 3. Properly informed about the study and has given written informed consent and parental consent (for her baby) in accordance with the International Conference on Harmonization Good Clinical Practice (ICH GCP) and local legislation prior to the first study intervention 4. Grants access to her own and her baby's study related medical records Exclusion Criteria 1. Previous vaccination with an investigational Group B Streptococcus (GBS) Vaccine 2. BMI of <17 or >40 at the time of screening 3. Human immunodeficiency virus (HIV), hepatitis B virus (HBV) and/or hepatitis C virus (HCV) positive or positive for syphilis 4. Knowingly carrying, at screening, a malformed or genetically abnormal foetus, incl. renal pelvis dilation, single umbilical artery (screening will be undertaken after the ultrasound conducted for the detection of anomalies) 5. Chronic or pregnancy induced hypertension at screening, >1+ protein in urine regardless of blood pressure or 1+ protein in urine and hypertension 6. Experienced a previous stillbirth prior to going into labour 7. Gestational, type 1 or type 2 diabetes 8. Potential placenta previa as per malformation ultrasound scan 9. Rhesus negative and has anti-D antibodies or other potential harmful antibodies 10. Known or suspected allergies to any components of the vaccine including to aluminium or aminoglycoside antibiotics, or an allergic reaction related to a previous vaccination 11. Fever (temperature >37.9°C) on the day of receiving the first dose or an acute infection in the 7 days before the first dose (the first dose can be delayed if gestational age permits) 12. Received systemic steroids in the 6 weeks before the first dose (inhaled and topical steroids are acceptable) 13. Any lesion (including tattoos) at the planned injection site that will impair the assessment of the injection site 14. Received immunosuppressive medication, chemotherapy or radiotherapy in the 24 weeks before the first dose 15. Received blood, blood products, plasma derivatives or any immunoglobulin preparations in the 12 weeks before the first dose 16. Anaemia, haemoglobin (<10 g/dL, 100 g/L, 6.2 mmol/L) 17. Currently breast feeding 18. Received any investigational medicinal product or vaccine in the 12 weeks or 5 half-lives before the first dose 19. Received an approved vaccine within the 4 weeks before the first dose or expects to receive an approved vaccine during the study. Routine vaccinations recommended during pregnancy (e.g., pertussis and influenza) are permitted but every effort should be made to separate routine vaccinations from the trial vaccinations by at least 7 days. 20. Known or suspected immunodeficiency or cancer (leukaemia, lymphoma), or a family history of congenital or hereditary immunodeficiency 21. History or presence of uncontrolled cardiovascular disease, pulmonary, hepatic, gall bladder or biliary tract, renal, haematological, gastrointestinal, endocrine, immunologic, dermatological, neurological, psychiatric, or autoimmune disease 22. History of, or current drug or alcohol abuse 23. In the opinion of the investigator not suitable for inclusion in the study 24. The pregnancy is considered high risk by treating physicians |
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University Hospital; Skejby | Aarhus | |
Denmark | Hvidovre University Hospital | Hvidovre | |
Denmark | Institut for Regional Sundhedsforskning | Kolding | |
South Africa | ESRU Rahima Moosa Mother and Child Hospital | Johannesburg | |
South Africa | Shandukani Research Clinic | Johannesburg | |
South Africa | Wits Vaccines & Infectious Diseases Analytics | Johannesburg | |
South Africa | Mecru Clinical Research Unit (MeCRU) | Pretoria | |
South Africa | Setshaba Research Centre | Pretoria | |
United Kingdom | St George's University Hospital | London | |
United Kingdom | University Hospital Southampton | Southampton |
Lead Sponsor | Collaborator |
---|---|
Minervax ApS | Larix A/S |
Denmark, South Africa, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Opsonophagocytic killing assay (OPKA) titres | OPKA titres in cord blood and maternal blood | Delivery | |
Other | Concentrations of IgG antibodies specific to the NN and NN2 fusion proteins in maternal blood | Concentrations of IgG antibodies specific to the NN and NN2 fusion proteins in maternal blood | 4 weeks after each dose; at delivery | |
Other | Concentrations of IgG and IgA antibodies specific to the AlpN proteins in colostrum and in breast milk | Concentrations of IgG and IgA antibodies specific to the AlpN proteins in colostrum and in breast milk | Within 48 hours of delivery; 1 month and 3 months post-delivery | |
Primary | Concentrations of Immunoglobulin (Ig) G antibodies specific to the AlpN proteins in µg/mL in cord blood from each baby | Concentrations of IgG antibodies specific to the AlpN proteins in µg/mL in cord blood from each baby | Delivery | |
Secondary | Injection site reactions in the mother | Number of participants with solicited injection site reactions following vaccination | To Day 84 | |
Secondary | Adverse events following the vaccinations in the mother | Number of participants with solicited and other adverse events following the vaccinations | To Day 84 | |
Secondary | Clinically significant abnormal laboratory tests in the mother | Number of participants with clinically significant abnormal laboratory tests in the mother | To Day 84 | |
Secondary | Clinically significant changes in vital signs in the mother | Number of participants with clinically significant changes in vital signs (heart rate,blood pressure, oral temperature) in the mother | To Day 84 | |
Secondary | Clinically significant changes in physical examination in the mother | Number of participants with clinically significant changes in physical examination in the mother | To Day 84 | |
Secondary | Gestational weight in the baby | Gestational weight in the baby | Delivery, 28 days, 90 days and 180 days post delivery. | |
Secondary | Weight in the baby | Weight in the baby | Delivery, 28 days, 90 days and 180 days post delivery. | |
Secondary | Length in the baby | Length in the baby | Delivery, 28 days, 90 days and 180 days post delivery. | |
Secondary | Head circumference in the baby | Head circumference in the baby | Delivery, 28 days, 90 days and 180 days post delivery. | |
Secondary | Apgar score in the baby | Apgar score in the baby, range 0 to 10 where high scores are good and low scores are bad | 1, 5 and 10 minutes | |
Secondary | Developmental milestones in the baby using Ages & Stages questionnaire | Developmental milestones in the baby using Ages & Stages questionnaire | 6 months | |
Secondary | Concentrations of IgG antibodies specific to the AlpN proteins in µg/mL in maternal blood | Concentrations of IgG antibodies specific to the AlpN proteins in µg/mL in maternal blood | Delivery | |
Secondary | Concentrations of IgG antibodies specific to the AlpN proteins in µg/mL in blood from each baby | Concentrations of IgG antibodies specific to the AlpN proteins in µg/mL in blood from each baby | 1 month, 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05832502 -
Clinical Trial Investigating the Safety and Immunogenicity of GBS6 in Pregnant Women With and Without HIV (PREPARE)
|
Phase 2 | |
Completed |
NCT02142933 -
Simplified GBS Screening and Prevalence of ESBL in Pregnant Women
|
N/A | |
Completed |
NCT04596878 -
Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV
|
Phase 2 | |
Withdrawn |
NCT04116645 -
Time Frame for GBS Screening
|
||
Terminated |
NCT02814318 -
Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization
|
||
Withdrawn |
NCT04227730 -
MATERNAL AND NEONATAL SCREENING FOR GROUP B STREPTOCOCCI : A Follow up STUDY
|
||
Completed |
NCT02528981 -
Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial
|
N/A | |
Recruiting |
NCT01577108 -
Oral Probiotics Reduce Group B Streptococci Colonization in Pregnant Women
|
Phase 2 |